Entera Bio Ltd. filed a Form 8-K with the SEC on October 27, 2026, disclosing the appointment of Juan Camilo Arjona Ferreira, M.D., as a Class II director effective December 1, 2026, and the concurrent departure of director Haya Taitel on the same date.

Key Highlights

  • New director appointed: Juan Camilo Arjona Ferreira, M.D., age 57, was appointed as a Class II director of Entera Bio Ltd., effective December 1, 2026.
  • Committee assignment: Dr. Arjona Ferreira was also appointed to serve as a member of the compensation committee of the Board, effective December 1, 2026.
  • Term of service: He will serve until the Company's 2027 Annual Meeting of Shareholders and until his successor is elected and qualified, or until earlier departure.
  • Director departure: Haya Taitel notified the Board on October 27, 2026, that she would step down as a director, also effective December 1, 2026.
  • Independence determination: The Board determined that Dr. Arjona Ferreira is independent under applicable SEC and Nasdaq Stock Market rules, according to the filing.
  • Compensation terms: Dr. Arjona Ferreira will participate in the Company's standard non-employee director compensation arrangements, most recently approved by shareholders in July 2026, including annual cash payments and equity grants under the Company's 2018 Equity Incentive Plan.

Entera Bio Names Pharmaceutical Executive to Board as Taitel Steps Down

According to the filing, Entera Bio Ltd. (NASDAQ:ENTX) disclosed on October 27, 2026, that its Board of Directors appointed Juan Camilo Arjona Ferreira, M.D., as a Class II director, with the appointment effective December 1, 2026. The filing states that Dr. Arjona Ferreira, age 57, has "more than 20 years of global clinical development experience" and is described as "a seasoned physician and pharmaceutical executive and a longtime global advocate for women's health."

The filing details that Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon and Co. (NYSE: OGN). Prior to that role, according to the filing, he served as Chief Medical Officer of Myovant Sciences Inc., Senior Vice President of Clinical Development at Shionogi Inc., and spent over a decade at Merck and Co., Inc. (NYSE: MRK), with his last role there as Executive Director of Clinical Research in Women's Health. The filing also notes that he earned his Medical Degree and completed specialist OB-GYN training at the Colegio Mayor del Rosario in Bogota, Colombia.

The filing states there are no arrangements or understandings between Dr. Arjona Ferreira and any other person pursuant to which he was appointed, and that the Company has not engaged in any transaction with him that would require disclosure under Item 404(a) of Regulation S-K since the beginning of the last fiscal year. Separately, the filing discloses that Haya Taitel notified the Board of her resignation as director, also effective December 1, 2026, and that "her departure from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices."

What Was Disclosed

Entera Bio filed an 8-K on October 27, 2026, reporting the Board appointment of Dr. Juan Camilo Arjona Ferreira as a Class II director and compensation committee member, effective December 1, 2026, alongside the resignation of director Haya Taitel on the same effective date.